Cullinan Therapeutics Inc's Comment on Supply Chain
Suppliers are required to comply with the FDA's Quality System Regulation, which governs the design, testing, production, processes, controls, quality assurance, labeling, packaging, and shipping of medical devices. Both domestic and foreign manufacturing facilities undergo FDA inspections. FDA-approved drugs and biologics are subject to ongoing regulation, including recordkeeping, reporting, product sampling, distribution, and restrictions on promotional activities, particularly concerning off-label uses. Promotional materials must be submitted to the FDA prior to their initial use. Product changes may necessitate new or supplemental FDA approvals. Post-approval obligations can include post-market testing and surveillance. Manufacturers and subcontractors must register with the FDA and adhere to current Good Manufacturing Practices (cGMP), with periodic unannounced inspections conducted. Failure to comply may result in legal or regulatory actions such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties, or criminal prosecution.
Cullinan Therapeutics Inc's Comment on Supply Chain
Suppliers are required to comply with the FDA's Quality System Regulation, which governs the design, testing, production, processes, controls, quality assurance, labeling, packaging, and shipping of medical devices. Both domestic and foreign manufacturing facilities undergo FDA inspections. FDA-approved drugs and biologics are subject to ongoing regulation, including recordkeeping, reporting, product sampling, distribution, and restrictions on promotional activities, particularly concerning off-label uses. Promotional materials must be submitted to the FDA prior to their initial use. Product changes may necessitate new or supplemental FDA approvals. Post-approval obligations can include post-market testing and surveillance. Manufacturers and subcontractors must register with the FDA and adhere to current Good Manufacturing Practices (cGMP), with periodic unannounced inspections conducted. Failure to comply may result in legal or regulatory actions such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties, or criminal prosecution.
Sources:
Cullinan Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Cullinan Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
